Calusterone (NSC-88536): a poor substitute for fluoxy-mesterone (NSC-12165) in the treatment of advanced breast cancer.
作者信息
Falkson G, van Dyk J J, van Eden E B, van der Merwe A M, FALKSON H C
出版信息
Cancer Chemother Rep. 1974 Nov-Dec;58(6):939-41.
PMID:4615788
Abstract
摘要
相似文献
1
Calusterone (NSC-88536): a poor substitute for fluoxy-mesterone (NSC-12165) in the treatment of advanced breast cancer.
Cancer Chemother Rep. 1974 Nov-Dec;58(6):939-41.
2
Letter: Calusterone (NSC-88536) in advanced breast cancer.
Cancer Treat Rep. 1976 Mar;60(3):220-1.
3
Calusterone therapy for advanced breast cancer.
Cancer Treat Rep. 1977 May-Jun;61(3):371-3.
4
Calusterone (7beta,17alpha-dimethyltestosterone) as primary and secondary therapy of advanced breast cancer.
Oncology. 1973;28(2):138-46. doi: 10.1159/000224811.
5
[Clinical considerations on the use of a new synthetic androgen, Calusterone, in the treatment of advanced breast cancer].
Minerva Med. 1977 Jul 28;68(36):2499-504.
6
Calusterone.
Ann Intern Med. 1978 Dec;89(6):945-8. doi: 10.7326/0003-4819-89-6-945.
7
Antitumor activity of calusteron (NSC-88536) in advanced breast cancer.
Cancer Chemother Rep. 1975 Sep-Oct;59(5):890-1.
8
[Trial hormone therapy of advanced breast cancers with calusterone. Preliminary study of 41 cases].
Sem Hop. 1974;50(50-51):3099-105.
9
Cytotoxic drug and hormone therapy after adrenalectomy for advanced breast cancer.
Surg Gynecol Obstet. 1968 Sep;127(3):538-42.
10
Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
Cancer Chemother Rep. 1973 Apr;57(2):225-30.
Zotero 插件